GreenRoc now on the EU radar after presentation on Amitsoq at the Greenland Business Mission. Watch the interview here.

Less Ads, More Data, More Tools Register for FREE
Sponsored Content
Sponsored Content

Pin to quick picksAbingdon Healt. Regulatory News (ABDX)

Share Price Information for Abingdon Healt. (ABDX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 9.00
Bid: 9.00
Ask: 9.50
Change: -0.25 (-2.70%)
Spread: 0.50 (5.556%)
Open: 9.25
High: 9.00
Low: 9.00
Prev. Close: 9.25

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Completion of Acquisition of Compliance Solutions

15 Aug 2024 15:50

RNS Number : 6544A
Abingdon Health PLC
15 August 2024
 

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF THE UK VERSION OF REGULATION (EU) NO 596/2014 WHICH IS PART OF UK LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED ("MAR"). UPON THE PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INSIDE INFORMATION IS NOW CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

 

Abingdon Health plc

("Abingdon Health" or "the Company")

 

Completion of Acquisition of Compliance Solutions

 

York, U.K. 15 August 2024: Abingdon Health plc (AIM: ABDX), a leading international lateral flow contract research (CRO) and contract development and manufacturing organisation (CDMO), is pleased to announce the completion of the acquisition of the CS Lifesciences group ("Compliance Solutions"), a consultancy business which specialises in meeting compliance (Quality/ Regulatory/ Clinical) requirements in international IVD and medical device markets.

  

Application has been made for the admission to trading on AIM ("Admission") for the 9,216,590 new initial Consideration shares (as defined in the announcement dated 24 July 2024). It is expected that Admission will become effective on 19 August 2024.

Following the issue of the new 9,216,590 initial Consideration shares the Company will have a total of 189,523,153 Ordinary Shares in issue. The Company does not hold any shares in Treasury.

 

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure Guidance and Transparency Rules.

 

The above information is provided by the Company in accordance with its obligations under the FCA's Disclosure Guidance and Transparency Rules.

 

The Company intends to launch, shortly, an offer to its retail shareholders at the same price as the recent placing, 9.75p per share.

  

Chris Yates, CEO, commented:

 

"We are delighted to welcome Edwin Lindsay and all the Compliance Solutions team to the Abingdon Health group. The acquisition of Compliance Solutions deepens and broadens Abingdon's regulatory service offering allowing us to fully support our customers in bringing their products from idea to commercial success."

 

Edwin Lindsay, Managing Director of Compliance Solutions, commented:

 

"We are delighted to join the Abingdon group and we look forward to working with the Abingdon team to support our growing customer base across the In Vitro Diagnostic and Medical Device Market. The regulatory landscape is going through a period of significant change and the enlarged group is well placed to support customers in navigating this complexity to achieve and maintain successful product registrations.".

 

 

Enquiries

 

Abingdon Health plc

www.abingdonhealth.com/investors/

Chris Yates, Chief Executive Officer

Via Walbrook PR

Chris Hand, Non-Executive Chairman

 

 

 

Zeus Capital Limited (Nominated Adviser and Broker)

Tel: +44 (0) 20 7220 1666

Chris Fielding / Isaac Hooper (Corporate Finance)

Fraser Marshall (Corporate Broking)

 

 

 

The person responsible for arranging the release of this announcement on behalf of the Company is Chris Yates, Chief Executive Officer of the Company.

 

About Abingdon Health plc

Abingdon Health is a leading lateral flow contract research (CRO) and contract development and manufacturing organisation (CDMO) offering its services to an international customer base across industry sectors that include clinical, animal health, plant health, and environmental testing. Abingdon Health has the internal capabilities to take projects from initial concept through to routine and large-scale manufacturing; from "idea to commercial success."

 

The Company's CDMO division offers product development, regulatory support, technology transfer and manufacturing services for customers looking to develop new assays or transfer existing laboratory-based assays to a lateral flow format. Abingdon Health aims to support the increase in need for rapid results across many industries and locations and produces lateral flow tests in areas such as infectious disease, clinical testing including companion diagnostics, animal health and environmental testing. Faster access to results allows for rapid decision making, targeted intervention and can support better outcomes. 

 

Abingdon Health's Abingdon Simply Test range of self-tests is an ecommerce platform that offers a range of self-tests to empowers consumers to manage their own health and wellbeing. The Abingdon Simply Test ecommerce site offers consumers a range of information to support them in making informed decisions on the tests available. In addition, the site provides Abingdon's contract services customers with a potential route to market for self-tests. The Abingdon Simply Test range is also sold through international distributors and through other channels in the UK and Ireland such as pharmacy chains.

 

Founded in 2008, Abingdon Health is headquartered in York, England.

For more information visit: www.abingdonhealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
ACQGPURCRUPCGCA
Date   Source Headline
4th Oct 20247:00 amRNSNotice of Results
29th Aug 20247:00 amRNSResults of the Retail Offer
27th Aug 20249:26 amRNSTR - 1
20th Aug 20243:44 pmRNSTR-1
19th Aug 20241:48 pmRNSTR-1
19th Aug 20241:48 pmRNSTR-1
19th Aug 20241:45 pmRNSTR-1
19th Aug 20249:00 amRNSRetail Offer Launch
15th Aug 20243:50 pmRNSCompletion of Acquisition of Compliance Solutions
12th Aug 202410:41 amRNSResult of General Meeting and Total Voting Rights
25th Jul 202411:52 amRNSResult of Placing
24th Jul 20244:51 pmRNSProposed Acquisition and Placing Notice of GM
15th Jul 20247:00 amRNSChange of Nominated Adviser and Broker
9th Jul 20247:00 amRNSTrading Update
31st May 20247:00 amRNSTotal Voting Rights – 31 May 2024
15th May 20247:00 amRNSLaunch of the Saliva Pregnancy self-test in Boots
8th May 20247:00 amRNSChange of Nominated Adviser and Sole Broker
7th May 20247:00 amRNSAcquisition of IVDeology Holdings Limited
25th Mar 20247:00 amRNSDesign freeze completion & strategic partnership
20th Mar 20247:00 amRNSLaunch of OEM self-tests in Boots
15th Mar 20241:00 pmRNSCEO Interview
14th Mar 20247:00 amRNSInterim Results
11th Mar 20248:53 amRNSNotice of Results
11th Jan 20247:01 amRNSUpdate to Shareholder Concert Parties
11th Jan 20247:00 amRNSTrading Update
15th Dec 202310:15 amRNSResult of AGM
15th Dec 20237:00 amRNSAGM Statement
22nd Nov 20237:00 amRNSNotice of Annual General Meeting
25th Oct 20237:00 amRNSDirector/PDMR Shareholding
24th Oct 20237:01 amRNSAward of Options under LTIP
24th Oct 20237:00 amRNSAppointment of Interim Finance Director
18th Oct 20237:00 amRNSDirectorate Change
17th Oct 20237:00 amRNSFinal Results
11th Oct 20237:00 amRNSNotice of Results
7th Sep 20237:00 amRNSPartnership with Morrama
30th Aug 20237:00 amRNSAgreed changes to Concert Party
15th Aug 20237:00 amRNSSalistick™ to be launched in Tesco
6th Jul 20237:00 amRNSTrading Update
19th Jun 20237:00 amRNSLaunch of Salistick™ saliva pregnancy test
31st Mar 20237:00 amRNSInterim Results
24th Mar 202312:30 pmRNSNotice of Results
20th Mar 20237:00 amRNSSenzo & Abingdon enter into strategic partnership
7th Mar 20237:00 amRNSAppDx® granted further patent
1st Mar 20237:00 amRNSDirector Share Transfer to Trust
28th Feb 20239:05 amRNSSecond Price Monitoring Extn
28th Feb 20239:00 amRNSPrice Monitoring Extension
28th Feb 20237:00 amRNSTrading Update
19th Dec 202210:29 amRNSResult of AGM
19th Dec 20227:01 amRNSAward of Options under new LTIP Scheme
19th Dec 20227:00 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Free Investment Tools

Register for FREE

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.